You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020153027
Dec 20202406
Jan 202147017
Feb 202126013
Mar 202182032
Apr 20215209
May 202133014
Jun 20210010
Jul 20210011
Aug 20210016
Sep 20210014
Oct 202124038
Nov 202142028
Dec 202148017
Jan 202238010
Feb 202214010
Mar 202238010
Apr 202273013
May 202242011
Jun 202242014
Jul 202232016
Aug 20223207
Sep 20223806
Oct 20223605
Nov 20223605
Dec 202258018
Jan 202326015
Feb 202390031
Mar 20233804
Apr 20233606
May 20234602
Jun 20231605
Jul 202356013
Aug 20233805
Sep 20233804
Oct 20235604
Nov 20239006
Dec 20238604
Jan 20242200
Feb 20246402
Mar 20248008
Apr 20244405
May 20245203
Jun 20243404
Jul 20245609
Aug 20242804
Sep 202428021
Oct 202458014
Nov 202476025
Dec 202464010
Jan 202540033
Feb 20251604
Mar 20250012
Apr 2025002
May 2025006
Jun 2025206
Total22900644